Table 2. Cox regression analysis of immunohistochemistry YAP1 expression and clinicopathological covariates in patients with CRC.

Characteristics	Disease-free Survival						Disease-specific Survival
	Univariate			Multivariate			Univariate			Multivariate
	HR (95%CI)	P Value		HR (95%CI)	P Value		HR (95%CI)	P Value		HR (95%CI)	P Value
YAP1-high vs. YAP1-low(cytoplasmic)	3.891 (2.758–5.490)	<0.001		3.255 (2.290–4.627)	<0.001		4.291 (2.545–7.236)	<0.001		4.049 (2.400–6.830)	<0.001
YAP1-low vs. YAP1-high(NCR)	2.709(1.331–5.511)	0.006		2.295(1.118–4.711)	0.024		3.346(1.219–9.183)	0.019		2.873(1.045–7.902)	0.041
YAP1-high vs. YAP1-low(nuclear)	0.684(0.453–1.031)	0.070					0.860(0.412–1.975)	0.688
Age (>=60 vs. <60)	0.897 (0.667–1.207)	0.474					0.891 (0.568–1.398)	0.617
Sex (female vs. male)	0.867 (0.638–1.177)	0.360					0.817 (0.512–1.302)	0.395
Location (colon vs. rectum)	1.068 (0.793–1.440)	0.665					1.159 (0.737–1.823)	0.522
TNM (per increase in stage)	1.874 (1.474–2.381)	<0.001		1.863 (1.471–2.360)	<0.001		1.256 (0.889–1.775)	0.196
Grade (per increase in grade)	3.001 (1.948–4.625)	<0.001		3.435 (2.127–5.548)	<0.001		2.992 (1.575–5.685)	0.001		2.732 (1.383–5.394)	0.004
Chemotherapy (yes vs. no)	1.705 (1.156–2.515)	0.007		1.029 (0.647–1.637)	0.902		1.125 (0.662–1.912)	0.663
Resected lymph nodes (≥12 vs. <12)	2.675 (1.689–4.236)	<0.001		1.780 (1.111–2.853)	0.017		2.610 (1.375–4.954)	0.003		1.685 (0.874–3.251)	0.120
Serum CEA (≥5 vs. <5 ng/ml)	1.646 (1.223–2.215)	0.001		1.513 (1.120–2.043)	0.007		1.378 (0.876–2.170)	0.166
Serum CA19-9 (≥37 vs. <37 U/ml)	1.766 (1.224–2.549)	0.002		1.350 (0.914–1.995)	0.132		1.619 (0.906–2.894)	0.104

Notes.

Abbreviations

HR

hazard ratio

CI

confidence interval

YAP1

Yes associated protein 1

TNM

tumor-node-metastasis

CEA

carcinoembryonic antigen

CA19-9

carbohydrate antigen 19-9

NCR

Nuclear/Cytoplasmic Ratio